CA2127805A1 - Composition for nasal administration - Google Patents

Composition for nasal administration

Info

Publication number
CA2127805A1
CA2127805A1 CA002127805A CA2127805A CA2127805A1 CA 2127805 A1 CA2127805 A1 CA 2127805A1 CA 002127805 A CA002127805 A CA 002127805A CA 2127805 A CA2127805 A CA 2127805A CA 2127805 A1 CA2127805 A1 CA 2127805A1
Authority
CA
Canada
Prior art keywords
agents
composition
nasal administration
morphine
promoting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002127805A
Other languages
French (fr)
Other versions
CA2127805C (en
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Lisbeth Illum
Danbiosyst Uk Limited
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Li Mited
Archimedes Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lisbeth Illum, Danbiosyst Uk Limited, West Pharmaceutical Services Drug Delivery & Clinical Research Centre Li Mited, Archimedes Development Limited filed Critical Lisbeth Illum
Publication of CA2127805A1 publication Critical patent/CA2127805A1/en
Application granted granted Critical
Publication of CA2127805C publication Critical patent/CA2127805C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

A composition for nasal administration of polar metabolites of opioid analgesics comprises a polar metabolite of an opioid analgesic and an absorption promoting agent. Preferred metabolites morphine-6-glucuronide and morphine-6-sulphate. A
preferred absorption promoting agent is chitosan but other suitable agents include cationic polymers, bioadhesive agents, surface active agents, fatty acids, chelating agents, mucolytic agents, cyclodextrin, microsphere preparations or combinations thereof.
CA002127805A 1992-02-05 1993-02-04 Composition for nasal administration Expired - Lifetime CA2127805C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9202464.5 1992-02-05
GB929202464A GB9202464D0 (en) 1992-02-05 1992-02-05 Composition for nasal administration
PCT/GB1993/000228 WO1993015737A1 (en) 1992-02-05 1993-02-04 Compositions for nasal administration containing polar metabolites of opioid analgesics

Publications (2)

Publication Number Publication Date
CA2127805A1 true CA2127805A1 (en) 1993-08-19
CA2127805C CA2127805C (en) 2004-03-30

Family

ID=10709891

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002127805A Expired - Lifetime CA2127805C (en) 1992-02-05 1993-02-04 Composition for nasal administration

Country Status (12)

Country Link
US (1) US5629011A (en)
EP (1) EP0625044B1 (en)
JP (1) JP3958352B2 (en)
AT (1) ATE171872T1 (en)
AU (1) AU665806B2 (en)
CA (1) CA2127805C (en)
DE (1) DE69321458T2 (en)
DK (1) DK0625044T3 (en)
ES (1) ES2123660T3 (en)
GB (2) GB9202464D0 (en)
NO (1) NO306283B1 (en)
WO (1) WO1993015737A1 (en)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247472B (en) * 1991-05-31 1994-12-17 Fidia Spa PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
DE69434304T2 (en) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmaceutical compositions for the intranasal administration of dihydroergotamine
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2282758A (en) * 1993-08-23 1995-04-19 Euro Celtique Sa Oral morphine-6-glucuronide compositions
DE4403709A1 (en) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmaceutical composition for systemic transdermal administration with the active ingredient morphine-6-glucuronide
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
WO1996002275A1 (en) * 1994-07-20 1996-02-01 Toyama Chemical Co., Ltd. Sustained-release oral ointment
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6403602B1 (en) * 1997-02-20 2002-06-11 The University Of Kentucky Research Foundation Morphine-6-sulfate analogues and their use for the treatment of pain
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
JP2005281315A (en) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc Aqueous pharmacological composition
IL133882A0 (en) * 1997-07-18 2001-04-30 Bayer Ag Process for making an intranasal drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JP4234803B2 (en) * 1997-10-27 2009-03-04 久光製薬株式会社 Pharmaceutical composition with controlled drug release rate
FR2771929B1 (en) * 1997-12-09 2001-02-23 Biovector Therapeutics USE IN A PHARMACEUTICAL COMPOSITION FOR THE NASAL DELIVERY OF HYDROPHILIC PARTICLES FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
ATE265846T1 (en) * 1998-02-25 2004-05-15 Abbott Lab SUSTAINED RELEASE FORMULATIONS CONTAINING BUTORPHANOL
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6608073B1 (en) * 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2787029A1 (en) * 1998-12-09 2000-06-16 Biovector Therapeutics USE IN A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF VITAMIN B12 FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
ES2197792B1 (en) 1999-06-16 2005-05-01 Nastech Pharmaceutical Co., Inc. PHARMACEUTICAL FORMULATIONS CONTAINING INTRANASAL MORPHINE.
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
WO2000076477A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Co., Inc. Methods and compositions for treating breakthrough pain
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6863896B1 (en) 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003522144A (en) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． Controlled release compositions comprising opioid agonists and antagonists
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
FR2811227A1 (en) * 2000-07-07 2002-01-11 Philippe Maincent PARTICULATE VECTORS FOR IMPROVING ORAL ABSORPTION OF ACTIVE PRINCIPLES
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP2311460A1 (en) * 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP2005501845A (en) 2001-08-16 2005-01-20 メディカル リサーチ カウンシル Chitin microparticles and their medical uses
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CA2487712A1 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006021996A (en) * 2002-07-04 2006-01-26 Dainippon Sumitomo Pharma Co Ltd Conjugated substance of substituted hydroxypyridine compound
PT1551372T (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and metohds
DE10248601B4 (en) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmaceutical agent for endonasal administration in the treatment of diseases and disorders of the central nervous system
US7445769B2 (en) * 2002-10-31 2008-11-04 Cadbury Adams Usa Llc Compositions for removing stains from dental surfaces and methods of making and using the same
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
MXPA05011644A (en) * 2003-04-30 2005-12-15 Nastech Pharm Co CLAUDINSaCOE UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS.
US20040248804A1 (en) * 2003-05-01 2004-12-09 Khurshid Iqbal Nasal administration of the LH-RH analog Leuprolide
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
US7641892B2 (en) * 2004-07-29 2010-01-05 Cadburry Adams USA, LLC Tooth whitening compositions and delivery systems therefor
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
NZ571965A (en) * 2006-03-30 2012-02-24 Engene Inc Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
PL2526932T3 (en) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
JP2010506833A (en) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド Pharmaceutical composition
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
EP2753302B1 (en) 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
CN111620830A (en) 2014-03-14 2020-09-04 北卡罗来纳大学教堂山分校 Small molecules for inhibiting male fertility
RU2017127734A (en) 2015-01-07 2019-02-07 Трайджемина, Инк. MAGNESIUM-CONTAINING COMPOSITIONS OF OXYTOCINE AND METHODS OF APPLICATION
FR3032353B1 (en) 2015-02-06 2017-03-10 Jacques Seguin PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN
CA3041308A1 (en) * 2016-10-21 2018-04-26 Somniferum Labs LLC Method, system and apparatus for controlled delivery of opioid and other medications
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
BR112019014408A2 (en) 2017-01-11 2020-04-28 Torrent Pharmaceuticals Ltd nasal composition of tapentadol
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
CN110257025B (en) * 2019-07-03 2020-07-03 中国石油大学(华东) Cyclodextrin microsphere ultra-high temperature fluid loss additive for water-based drilling fluid, preparation method thereof, water-based drilling fluid and application thereof
US20230372327A1 (en) * 2020-10-15 2023-11-23 Pharmbiotest Poland Sp. z o. o. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3602370A1 (en) * 1986-01-27 1987-08-06 Chrubasik Sigrun Use of analgesics by inhalation
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
ES2094809T3 (en) * 1990-03-30 1997-02-01 Yasunori Morimoto ABSORBABLE COMPOSITION BY VIA PERCUTANEA OF MORPHINE CHLORHYDRATE.
FR2665357B1 (en) * 1990-07-31 1995-03-31 Aiache Jean Marc PROCESS FOR THE PREPARATION OF A BIO-ADHESIVE GALENIC FORM AND GALENIC FORM THUS PREPARED.
JPH07505655A (en) * 1992-04-13 1995-06-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Delta-opioid receptor-selective benzylidene-substituted morphinan for the treatment of alcohol abuse

Also Published As

Publication number Publication date
AU3458093A (en) 1993-09-03
GB2277682B (en) 1995-12-20
NO942787D0 (en) 1994-07-27
EP0625044A1 (en) 1994-11-23
ES2123660T3 (en) 1999-01-16
NO942787L (en) 1994-07-27
US5629011A (en) 1997-05-13
WO1993015737A1 (en) 1993-08-19
ATE171872T1 (en) 1998-10-15
DE69321458T2 (en) 1999-03-18
JP3958352B2 (en) 2007-08-15
GB9413102D0 (en) 1994-08-31
DK0625044T3 (en) 1999-06-21
GB2277682A (en) 1994-11-09
GB9202464D0 (en) 1992-03-18
NO306283B1 (en) 1999-10-18
EP0625044B1 (en) 1998-10-07
DE69321458D1 (en) 1998-11-12
CA2127805C (en) 2004-03-30
JPH07503481A (en) 1995-04-13
AU665806B2 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
CA2127805A1 (en) Composition for nasal administration
AU5255996A (en) Topical formulation for local delivery of a pharmaceutically active agent
EP0995434A3 (en) Medicinal aerosol formulations
WO1996040086A3 (en) Compositions and methods for topical administration of pharmaceutically active agents
AU5159490A (en) Composition and method for administration of pharmaceutically active substances
EP0679390A3 (en) Sprayable topical pharmaceutical compositions
AU4359096A (en) An inhalation device, a method of dispersing a pharmaceutically active substance and a method of administering a dose of pharmaceutically active substance
AU6062590A (en) Pharmaceutically active compounds
CA2184433A1 (en) Retinoid Formulations in Porous Microspheres for Reduced Irritation and Enhanced Stability
AU6338396A (en) Intra-cavity therapeutic agent delivery device
CA2264960A1 (en) External formulation containing loxoprofen
AU5538098A (en) A slow releasing physiologically active pharmaceutical and method of preparation thereof
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
CA2282345A1 (en) Pharmaceutical composition
CA2274485A1 (en) Medicinal composition
CA2149013A1 (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
CA2168249A1 (en) Psoriasis treatment
CA2239352A1 (en) Injectable quinolone formulations
AU1470195A (en) Nanoparticles containing an active substance and a ketalizedpolytartramidic acid, process for their preparation, and use thereof
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent
CA2011063A1 (en) Nicardipine pharmaceutical composition for parenteral administration
AU3176695A (en) Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
WO2000035418A3 (en) Chewable drug delivery system
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
AU2187197A (en) Transdermally administered acetylcysteine as mucolytic agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20130204